Fox Run Management L.L.C. Takes Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Fox Run Management L.L.C. acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,422 shares of the biopharmaceutical company’s stock, valued at approximately $466,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ACAD. SG Americas Securities LLC raised its stake in shares of ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after purchasing an additional 1,966,607 shares during the last quarter. Barclays PLC increased its holdings in ACADIA Pharmaceuticals by 126.2% in the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after buying an additional 154,854 shares in the last quarter. Burney Co. purchased a new position in ACADIA Pharmaceuticals in the 4th quarter worth about $6,953,000. Proficio Capital Partners LLC bought a new position in ACADIA Pharmaceuticals during the 4th quarter valued at about $272,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of ACADIA Pharmaceuticals by 259.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock valued at $3,439,000 after acquiring an additional 161,331 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ACAD. Morgan Stanley reissued an “equal weight” rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Deutsche Bank Aktiengesellschaft assumed coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $23.93.

Insider Transactions at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares of the company’s stock, valued at $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 6,167 shares of company stock valued at $114,583 over the last three months. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Trading Down 0.7 %

NASDAQ ACAD opened at $17.11 on Wednesday. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.15 and a 12 month high of $20.68. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 21.94 and a beta of 0.43. The company’s 50 day moving average is $18.36 and its two-hundred day moving average is $17.02.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.